Headline News

 

ViiV Healthcare received positive CHMP opinion for long-acting regimen for the treatment of HIV

Posted on October 20, 2020

Forxiga recommended for approval in the EU by CHMP

Posted on October 20, 2020

Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD

Posted on October 20, 2020

Novartis receives positive CHMP opinion for Leqvio®

Posted on October 20, 2020

First Treatment for Ebola Virus Approved by FDA

Posted on October 20, 2020

Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 Announced by Moderna

Posted on October 20, 2020

Moderna Received Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19

Posted on October 20, 2020

U.S. FDA Accepts for Priority Review Applications for OPDIVO® in Combination with CABOMETYX® in Advanced Renal Cell Carcinoma

Posted on October 20, 2020

Positive CHMP Opinion Given to Bristol Myers Squibb Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Posted on October 20, 2020

Regulatory Applications submitted by AbbVie to FDA and EMA for RINVOQ™ in Atopic Dermatitis

Posted on October 20, 2020

What Is the Phase 3 Clinical Trial?

Posted on October 15, 2020

AZD7442 COVID-19 Long-Acting AntiBody combination rapidly advances into Phase III clinical trials

Posted on October 13, 2020

J&J Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine Candidate

Posted on October 13, 2020

DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

Posted on October 13, 2020

Moderna Announced Update on Respiratory Syncytial Virus (RSV) Vaccine Program

Posted on October 13, 2020